Bicocca Open Archive

Logo unimib boa
CECCON, MONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.839
AS - Asia 2.041
EU - Europa 1.880
SA - Sud America 301
AF - Africa 64
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.131
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.638
SG - Singapore 748
CN - Cina 440
IT - Italia 391
DE - Germania 344
VN - Vietnam 266
HK - Hong Kong 242
RU - Federazione Russa 230
BR - Brasile 214
IE - Irlanda 193
SE - Svezia 191
CA - Canada 178
GB - Regno Unito 130
UA - Ucraina 96
FR - Francia 82
IN - India 75
FI - Finlandia 52
AT - Austria 42
BD - Bangladesh 35
AR - Argentina 33
TR - Turchia 32
PL - Polonia 31
IQ - Iraq 28
ID - Indonesia 27
JP - Giappone 26
KR - Corea 24
ZA - Sudafrica 24
BE - Belgio 21
ES - Italia 21
PK - Pakistan 19
NL - Olanda 15
DK - Danimarca 14
MA - Marocco 14
CO - Colombia 12
MX - Messico 12
SA - Arabia Saudita 12
VE - Venezuela 11
CL - Cile 8
UZ - Uzbekistan 8
EC - Ecuador 7
LT - Lituania 7
PH - Filippine 7
PY - Paraguay 7
JO - Giordania 6
KE - Kenya 6
TN - Tunisia 6
IR - Iran 5
NP - Nepal 5
PE - Perù 5
TH - Thailandia 5
AZ - Azerbaigian 4
BG - Bulgaria 4
PS - Palestinian Territory 4
AU - Australia 3
BO - Bolivia 3
DZ - Algeria 3
KG - Kirghizistan 3
MY - Malesia 3
NG - Nigeria 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KZ - Kazakistan 2
MU - Mauritius 2
PA - Panama 2
SI - Slovenia 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
JM - Giamaica 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
NI - Nicaragua 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
Totale 8.129
Salva come PNG Salva come JPEG
Città #
Ann Arbor 502
Singapore 402
Ashburn 331
Hong Kong 240
San Jose 226
Frankfurt am Main 223
Fairfield 207
Chandler 206
Woodbridge 206
Milan 201
Dublin 190
Houston 158
Wilmington 137
Toronto 113
Dearborn 107
New York 107
Jacksonville 90
Los Angeles 89
Seattle 89
Cambridge 74
Beijing 70
Ho Chi Minh City 70
Santa Clara 66
Hanoi 63
Princeton 53
Nanjing 47
Chicago 45
Dallas 43
The Dalles 43
Vienna 36
Munich 29
Hefei 28
Lauterbourg 28
São Paulo 28
Boardman 26
Shanghai 26
Altamura 24
Council Bluffs 24
Lawrence 23
Buffalo 22
Nanchang 22
Seoul 21
Brussels 19
Warsaw 19
Helsinki 18
Montreal 18
Moscow 18
Jakarta 17
San Diego 17
Tokyo 17
Da Nang 16
Orem 16
Washington 16
Denver 15
Lachine 15
Rome 15
Turku 15
Brooklyn 14
Fremont 13
Guangzhou 13
Johannesburg 13
Rio de Janeiro 13
Göttingen 12
Chennai 11
London 11
Phoenix 11
Atlanta 10
Norwalk 10
Poplar 10
Trento 10
Baghdad 9
Falls Church 9
Haiphong 9
Hangzhou 9
Lahore 9
Lissone 9
Manchester 9
Newark 9
Pune 9
Salt Lake City 9
Andover 8
Ottawa 8
Shenyang 8
Tianjin 8
Amsterdam 7
Brasília 7
Chengdu 7
Edmonton 7
Jiaxing 7
Lodz 7
San Francisco 7
Stockholm 7
Taizhou 7
Tashkent 7
Amman 6
Boston 6
Düsseldorf 6
Hebei 6
Kunming 6
Nuremberg 6
Totale 5.365
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 543
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 451
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 434
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 404
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 383
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib 360
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 336
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 336
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 335
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 314
In Vitro and in Vivo Characterization of Bosutinib as Substrate of the Pglycoprotein Efflux Transporter 288
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 285
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 281
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth 277
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 272
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 265
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 262
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 245
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 234
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 229
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 228
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 227
Discovery of Novel α-Carboline Inhibitors of the Anaplastic Lymphoma Kinase 216
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 209
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 206
Crizotinib-resistan NPM-ALK mutants confer differential sensitivity to unrelated alk inhibitors 204
Synergistic drug combinations preventdrug resistance in anaplastic large cell lymphomapreclinical models 190
Identification of non-ATP-competitive α-carboline inhibitors of the anaplastic lymphoma kinase 177
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 157
Totale 8.348
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202159 0 0 0 0 0 0 0 0 0 0 0 59
2021/2022353 27 33 24 13 30 40 20 25 18 39 32 52
2022/2023849 83 244 88 88 60 114 8 58 52 20 19 15
2023/2024523 16 18 24 25 58 169 101 12 36 9 2 53
2024/20251.115 67 114 57 54 100 42 75 31 134 181 90 170
2025/20263.092 362 137 226 384 386 150 426 118 263 262 199 179
Totale 8.348